Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.2K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

981
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
981
Angina IV: Management01:26

Angina IV: Management

192
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
192
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

186
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
186
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.

Vascular medicine (London, England)·2021
Same author

Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.

Diabetes, obesity & metabolism·2021
Same author

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS Program.

Diabetologia·2021
Same author

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

European heart journal·2021
Same author

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.

Diabetologia·2021
Same author

Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.

Diabetes, obesity & metabolism·2021
Same journal

Breast cancer and coronary artery disease: insights from a national inpatient sample analysis.

Future cardiology·2026
Same journal

Mitral valve dysplasia associated with left ventricular non-compaction cardiomyopathy and papillary muscle hypertrophy: a case report.

Future cardiology·2026
Same journal

Cardio-oncology awareness: a multidisciplinary survey among trainees and practicing professionals at multidisciplinary settings.

Future cardiology·2026
Same journal

Wearable devices for atrial fibrillation: diagnostic and screening roles of ECG and PPG-A systematic review.

Future cardiology·2026
Same journal

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.

Future cardiology·2026
Same journal

Endovascular revascularisation of lower-extremity peripheral arterial disease: technical and clinical outcomes in a Vietnamese single-center prospective cohort study.

Future cardiology·2026
See all related articles

Related Experiment Video

Updated: Dec 28, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K

Cangrelor in clinical use.

Kent Y Feng1, Kenneth W Mahaffey1

  • 1Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

Future Cardiology
|February 19, 2020
PubMed
Summary
This summary is machine-generated.

Cangrelor, an intravenous P2Y12 inhibitor, effectively reduces complications during percutaneous coronary intervention (PCI). It offers a potent alternative to clopidogrel for patients needing immediate antiplatelet therapy.

Keywords:
P2Y12 inhibitoracute coronary syndromeantiplateletcangrelormyocardial infarctionpercutaneous coronary intervention

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

745

Related Experiment Videos

Last Updated: Dec 28, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.7K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.7K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

745

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute coronary syndrome and percutaneous coronary intervention (PCI) patients face risks from inadequate antiplatelet effects.
  • Clopidogrel is a common P2Y12 inhibitor, but its limitations necessitate alternatives.

Purpose of the Study:

  • To review the role of P2Y12 inhibition in PCI.
  • To discuss cangrelor's pharmacology, clinical profile, and benefits in PCI.
  • To highlight cangrelor as a treatment option for reducing periprocedural complications.

Main Methods:

  • Review of existing randomized controlled trials and clinical data.
  • Analysis of cangrelor's pharmacokinetic and pharmacodynamic properties.
  • Comparison of cangrelor's efficacy and safety against clopidogrel.

Main Results:

  • Cangrelor demonstrates rapid onset and potent P2Y12 inhibition.
  • Large trials show cangrelor reduces periprocedural complications in PCI compared to clopidogrel.
  • Benefits include reduced myocardial infarction, repeat revascularization, and stent thrombosis.

Conclusions:

  • Cangrelor is a valuable option for P2Y12 inhibition in PCI patients not yet on other inhibitors.
  • Consider cangrelor to mitigate risks of myocardial infarction, repeat revascularization, and stent thrombosis.
  • Further research into cangrelor's long-term applications and future directions is warranted.